ATE228824T1 - Liposomenzusammensetzung - Google Patents

Liposomenzusammensetzung

Info

Publication number
ATE228824T1
ATE228824T1 AT97940250T AT97940250T ATE228824T1 AT E228824 T1 ATE228824 T1 AT E228824T1 AT 97940250 T AT97940250 T AT 97940250T AT 97940250 T AT97940250 T AT 97940250T AT E228824 T1 ATE228824 T1 AT E228824T1
Authority
AT
Austria
Prior art keywords
polynucleotide
liposomes
cationic
liposome composition
dotap
Prior art date
Application number
AT97940250T
Other languages
German (de)
English (en)
Inventor
Gregory Gregoriadis
Square Brunswick
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619172.1A external-priority patent/GB9619172D0/en
Priority claimed from GBGB9625917.1A external-priority patent/GB9625917D0/en
Priority claimed from GBGB9713994.3A external-priority patent/GB9713994D0/en
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE228824T1 publication Critical patent/ATE228824T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT97940250T 1996-09-13 1997-09-15 Liposomenzusammensetzung ATE228824T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9619172.1A GB9619172D0 (en) 1996-09-13 1996-09-13 Liposomes
GBGB9625917.1A GB9625917D0 (en) 1996-12-13 1996-12-13 Liposomes
GBGB9713994.3A GB9713994D0 (en) 1997-07-01 1997-07-01 Liposomes
PCT/GB1997/002490 WO1998010748A1 (en) 1996-09-13 1997-09-15 Liposomes

Publications (1)

Publication Number Publication Date
ATE228824T1 true ATE228824T1 (de) 2002-12-15

Family

ID=27268476

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97940250T ATE228824T1 (de) 1996-09-13 1997-09-15 Liposomenzusammensetzung
AT02016936T ATE395904T1 (de) 1996-09-13 1997-09-15 Liposome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02016936T ATE395904T1 (de) 1996-09-13 1997-09-15 Liposome

Country Status (11)

Country Link
US (1) US7790696B2 (enExample)
EP (2) EP1254657B1 (enExample)
JP (1) JP2001502299A (enExample)
KR (1) KR100507660B1 (enExample)
CN (1) CN1138533C (enExample)
AT (2) ATE228824T1 (enExample)
AU (1) AU728581B2 (enExample)
CA (1) CA2271388C (enExample)
DE (2) DE69717661T2 (enExample)
ES (2) ES2305157T3 (enExample)
WO (1) WO1998010748A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146907A2 (en) * 1999-02-05 2001-10-24 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
WO2001024773A1 (en) * 1999-10-01 2001-04-12 Lipoxen Technologies Limited Liposome-entrapped dna oral vaccines
ATE274901T1 (de) 1999-12-13 2004-09-15 Lipoxen Technologies Ltd Liposomen enthaltend einen komplex aus polyanion und calciumphosphat
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US7604803B2 (en) 2002-07-05 2009-10-20 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP4546115B2 (ja) * 2004-03-05 2010-09-15 三菱化学メディエンス株式会社 細胞中ａｔｐの定量法
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN100400667C (zh) * 2006-06-27 2008-07-09 浙江大学 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途
EP2113511A4 (en) 2006-12-22 2010-09-15 Soluciones Biotecnologicas Inn DNA VACCINES FOR FISH
RU2367443C1 (ru) * 2008-02-28 2009-09-20 Общество с ограниченной ответственностью "Битеп" Средство на основе природных фосфолипидов
EP2184054A1 (en) 2008-11-08 2010-05-12 Lipoxen Technologies Limited Small Interfering RNA Delivery
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) * 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9408914B2 (en) * 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
PL2590676T3 (pl) 2010-07-06 2017-02-28 Glaxosmithkline Biologicals Sa Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
MX2014015041A (es) * 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
US20160324986A1 (en) * 2013-12-27 2016-11-10 Teloregen, Inc. Compositions and methods for providing active telomerase to cells in vivo
JP6546195B2 (ja) * 2014-01-17 2019-07-17 フンダシオ・インスティトゥート・ディンベスティガシオ・エン・シエンシス・デ・ラ・サルー・ヘルマンス・トリアス・イ・プホル リポソームに基づく免疫療法
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
US20220333178A1 (en) 2021-03-22 2022-10-20 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
EP0172007B1 (en) 1984-08-10 1991-05-22 Syntex (U.S.A.) Inc. Stable liposomes with aqueous-soluble medicaments and methods for their preparation
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
ZA8681B (en) 1985-01-07 1987-08-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
JP2627899B2 (ja) * 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US4882172A (en) * 1988-04-08 1989-11-21 Nabisco Brands, Inc. System for processing chewing gum
JP2923296B2 (ja) * 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) * 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69418334T2 (de) * 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
AU683957B2 (en) * 1993-11-05 1997-11-27 Amgen, Inc. Liposome preparation and material encapsulation method
NZ276305A (en) * 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
DE69634084T2 (de) * 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes

Also Published As

Publication number Publication date
DE69717661T2 (de) 2003-09-25
EP0938298B1 (en) 2002-12-04
US20080286353A1 (en) 2008-11-20
CN1237102A (zh) 1999-12-01
ATE395904T1 (de) 2008-06-15
EP1254657B1 (en) 2008-05-21
EP1254657A3 (en) 2003-03-05
AU728581B2 (en) 2001-01-11
KR20000036088A (ko) 2000-06-26
DE69717661D1 (de) 2003-01-16
CA2271388C (en) 2007-11-06
KR100507660B1 (ko) 2005-08-10
CN1138533C (zh) 2004-02-18
EP1254657A2 (en) 2002-11-06
AU4215497A (en) 1998-04-02
JP2001502299A (ja) 2001-02-20
US7790696B2 (en) 2010-09-07
WO1998010748A1 (en) 1998-03-19
ES2187812T3 (es) 2003-06-16
EP0938298A1 (en) 1999-09-01
CA2271388A1 (en) 1998-03-19
DE69738719D1 (de) 2008-07-03
ES2305157T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
DE69717661D1 (de) Liposomenzusammensetzung
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
WO2001034801A3 (en) Recombinant gelatin in vaccines
DE69536091D1 (de) Immunisierung durch Impfung von DNS Transkriptionseinheit
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
AU6803198A (en) Vaccines
WO1997038010A3 (en) Fusogenic liposomes
FI971530A7 (fi) Lipaasi, sitä tuottava mikro-organismi, menetelmä lipaasin valmistamis eksi ja sen käyttö
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO2000071154A3 (de) Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort
EP0904393A4 (en) PARAPOXVIRUS VECTORS
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
AU3926097A (en) Improved inactivated vaccines
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
WO1993017115A3 (en) Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
WO1999016466A3 (en) Vaccine compositions and methods of enhancing vaccine efficacy
NZ504993A (en) A vaccine comprising a pathogen that over-expresses a homologous antigen
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
WO2003018018A3 (en) Vinorelbine compositions and methods of use
WO2000016746A8 (en) Immunogenic liposome compositions
WO1999015669A3 (fr) Toxine de clostridium, et procede de preparation de compositions immunogenes
PT1469721E (pt) Método para determinar a imunogenicidade de proteínas que produzem uma resposta imunogénica modificada
Matveev et al. Preparation of liposomes from yeast phospholipids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties